Astrazeneca Ab

Medimmune Limited

Ina Terstiege

Anna Ingrid Kristina Berggren

Stefan Schiesser

Shawn Donald Johnstone

Roland Bürli

Yafeng Xue

Johan Bartholomeus

Rebecca Jarvis

Thor Ostenfeld

Massimiliano Travagli

Stephane Turcotte

Hui-Fang Chang

The present application relates to chemical compounds of Formula (A), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and can be used to treat respiratory diseases, cancer, inflammatory diseases, and/or autoinflammatory/autoimmune diseases. Formula (A): Rand Rare herein defined throughout the disclosure.

Substituted indazoles as IRAK4 inhibitors

The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.

IRAK4 inhibitors

The present application relates to chemical compounds of Formula (A): and pharmaceutically acceptable salts thereof, wherein X, R, and Rare as defined herein. The chemical compounds of Formula (A) inhibit IRAKand consequently have potential utility in medicine.

The present application relates to compounds of formula (I') or formula (I), such as formula (Ia), and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington disease (HD) and other CAG-triplet repeat (or polyglutamine) diseases, amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease), diffuse Lewy body disease, chorea-acanthocytosis, primary lateral sclerosis, multiple sclerosis (MS), frontotemporal dementia, Friedreich's ataxia, acute head injury, and epilepsy (repression of microglia activation).

Small molecule modulators of the BTB domain of Keap1

Growing community of inventors

Södertälje, Sweden

Ina Terstiege